

*The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.*

## **Proposal for resolution on authorization for the board of directors to resolve on new issues of ordinary shares**

In order to enable new issues of ordinary shares as guarantee compensation to those that have entered into guarantee undertakings in order to secure the rights issue of units as described below (the “**Guarantors**”), the board of directors of Alligator Bioscience AB, Reg. No. 556597-8201, proposes that the extraordinary general meeting on 24 April 2023 resolves to authorize the board of directors, up until the next annual general meeting, at one or several occasions, with deviation from the shareholders’ preferential rights, and with or without provisions regarding set-off or other provisions, to resolve on new issues of ordinary shares to the Guarantors. Upon exercise of the authorization, the subscription price shall correspond to 90 per cent of the volume-weighted average price (VWAP) for the company’s ordinary share on Nasdaq Stockholm during the subscription period in the rights issue of units resolved by the board of directors on 22 March 2023, and which is proposed for approval under item 8 on the agenda of the extraordinary general meeting (i.e. during the period 28 April 2023 – 12 May 2023), however, no lower than the subscription price in the rights issue.

The purpose of the authorization and reason for the deviation from the shareholders’ preferential rights is to be able to carry out new issues of ordinary shares as guarantee compensation to the Guarantors. The number of ordinary shares that may be issued through the authorization shall not exceed the total number of ordinary shares that corresponds to the agreed guarantee compensation that the company shall pay to the Guarantors.

The resolution presupposes and is conditional on the extraordinary general meeting resolving to amend the Articles of Association, to decrease the share capital as well as to approve the board of directors’ resolution on rights issue of units in accordance with the board of directors’ proposal to the meeting.

---

The company’s CEO shall be authorized to make such minor formal adjustments of the resolution as might be necessary in connection with registration with the Swedish Companies Registration Office (Sw. Bolagsverket).

For a valid resolution, the proposal has to be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the general meeting.

---

Lund in March 2023

The Board of Directors of Alligator Bioscience AB (publ)